| Literature DB >> 27274780 |
Mengting Liu1, Liying Tang1, Xin Liu1, Jing Fang1, Hao Zhan1, Hongwei Wu1, Hongjun Yang1.
Abstract
In recent years, metabolomics analyses have been widely applied to cerebral ischemia research. This paper introduces the latest proceedings of metabolomics research on cerebral ischemia. The main techniques, models, animals, and biomarkers of cerebral ischemia will be discussed. With analysis help from the MBRole website and the KEGG database, the altered metabolites in rat cerebral ischemia were used for metabolic pathway enrichment analyses. Our results identify the main metabolic pathways that are related to cerebral ischemia and further construct a metabolic network. These results will provide useful information for elucidating the pathogenesis of cerebral ischemia, as well as the discovery of cerebral ischemia biomarkers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27274780 PMCID: PMC4871976 DOI: 10.1155/2016/9162074
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Contrast of different methods/models and animals in cerebral ischemia.
| Model | Animal | Feature | Reference | |
|---|---|---|---|---|
| Global cerebral ischemia | Two-vessel occlusion (2VO) | Rat | High success rate, obviously damaged after ischemia/reperfusion; inducing whole-body hypotension in model preparation; influencing blood supply of other organs; it cannot be prepared in awake state, so neurobehavior assessment is infeasible | [ |
| Three-vessel occlusion (3VO) | Rat | Rapidly and effectively triggering ischemia; quickly recovering after reperfusion; suitable for acute whole-brained ischemia case, severe operation wound | [ | |
| Four-vessel occlusion (4VO) | Rat, rabbit | Suitable for subacute case; it can operate in both anesthetized and awake states; reperfusion is feasible; high mortality rate of animals | [ | |
|
| ||||
| Focal cerebral ischemia | Craniotomy method | Rat, mouse, cat, dog, pig | Accurate and reliable, consistent experimental conditions, high success rate, severe surgical damage; it cannot apply reperfusion, intracranial pressure increase in surgery, damage of blood-brain barrier, change of brain temperature | [ |
| Thromboembolic model | Rat, mouse | Imitating in situ cerebral ischemia; it can evaluate the efficacy of thrombolytic agents, three types including microemboli suspension, single embolus, and multiemboli model | [ | |
| Nonclot embolic model | Rat, mouse, monkey | Using artificial materials to replace natural clot to avoid self-thrombolysis; the volume of embolus is adjustable and able to totally block the target artery, reduce the influence of uncontrollable reperfusion, and precisely control the time point of ischemia/reperfusion and may cause inflammatory response | [ | |
| Intraluminal suture model | Rat, mouse | Well-reproducible, precise site of damage, precisely controllable time of ischemia; the operation of filament insertion into cranium cannot be directly observed and may cause hemorrhage and/or vasospasm | [ | |
| Chemical induction model | Rat, mouse | Chemicals stimulate the vessels and induce vasoconstriction or directly produce clots | [ | |
Amino acids metabolites in cerebral ischemia.
| Metabolites | Plasma | Serum | CSF | Cortex | Hippocampus | Striatum | Thalamus | Midbrain | Whole brain tissue | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Tyrosine | √ | √ | √ | [ | ||||||
| Serine | √ | √ | [ | |||||||
| Dopamine | √ | √ | √ | √ | √ | [ | ||||
| Alanine | √ | √ | √ | √ | √ | [ | ||||
| Citrulline | √ | √ | [ | |||||||
| Methionine | √ | [ | ||||||||
|
| √ | √ | √ | [ | ||||||
| Threonine | √ | [ | ||||||||
| Glutamate | √ | √ | √ | √ | [ | |||||
| Valine | √ | √ | √ | [ | ||||||
| Tryptophan | √ | √ | √ | [ | ||||||
| Serotonin | √ | √ | √ | √ | √ | [ | ||||
| Glycine | √ | √ | √ | [ | ||||||
| Phenylalanine | √ | √ | √ | [ | ||||||
| Glutamine | √ | √ | √ | [ | ||||||
| Glutamic acid | √ | √ | √ | [ | ||||||
| Histidine | √ | √ | √ | [ | ||||||
| Aspartate | √ | √ | √ | √ | [ | |||||
| Isoleucine | √ | √ | √ | [ | ||||||
| Leucine | √ | √ | [ | |||||||
| Nicotinuric acid | √ | √ | [ | |||||||
| Homocysteine | √ | [ | ||||||||
| Lysine | √ | [ | ||||||||
| Ornithine | √ | [ | ||||||||
| Arginine | √ | √ | [ |
Nucleic acids metabolites in cerebral ischemia.
| Metabolites | Cortex | Striatum | Whole brain tissue | Reference |
|---|---|---|---|---|
| UMP | √ | √ | [ | |
| UDP | √ | √ | √ | [ |
| UDP-glucose | √ | √ | [ | |
| UTP | √ | [ | ||
| Uridine | √ | √ | [ | |
| Uracil | √ | √ | √ | [ |
| Guanosine | √ | √ | [ | |
| GMP | √ | √ | [ | |
| Cytidine | √ | √ | [ | |
| CDP-choline | √ | √ | [ | |
| CMP | √ | √ | [ | |
| ATP | √ | √ | √ | [ |
| AMP | √ | √ | [ | |
| ADP | √ | √ | [ | |
| Ribose 5-phosphate | √ | √ | [ | |
| Neu5Ac | √ | √ | [ | |
| Xanthine | √ | √ | √ | [ |
| Pseudouridine | √ | √ | [ | |
| PE | √ | √ | [ | |
| PEP | √ | √ | [ |
UMP: uridine monophosphate; UDP: uridine diphosphate; UTP: uridine-5′-triphosphate; GMP: guanosine 5′-phosphate; CDP-choline: cytidine 5′-diphosphocholine; CMP: cytidine-5′-monophosphate; ATP: adenosine 5′-triphosphate; AMP: adenosine 5′-monophosphate; ADP: adenosine 5′-diphosphate; Neu5Ac: N-acetylneuraminate; PE: phosphoethanolamine; PEP: phosphoenolpyruvate.
Neurotransmitter metabolites in cerebral ischemia.
| Metabolites | Plasma | Serum | CSF | Cortex | Hippocampus | Striatum | Thalamus + midbrain | White matter | Whole brain tissue | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Dopamine (DA) | √ | √ | √ | √ | [ | |||||
| Norepinephrine (NE) | √ | √ | √ | √ | [ | |||||
| Serotonin (5-HT) | √ | √ | √ | √ | [ | |||||
| 3-Methoxy-4-hydroxyphenylglycol (MHPG) | √ | √ | √ | √ | [ | |||||
| 3,4-Dihydroxyphenylacetic acid (DOPAC) | √ | √ | √ | √ | [ | |||||
| Homovanillic acid (HVA) | √ | √ | √ | √ | [ | |||||
| 5-Hydroxyindoleacetic acid (5-HIAA) | √ | √ | √ | √ | [ | |||||
| GABA | √ | √ | √ | [ | ||||||
| Glutamic acid | √ | √ | √ | [ | ||||||
| Glycine | √ | √ | √ | [ | ||||||
| Glutamate | √ | √ | √ | √ | [ | |||||
| Aspartate | [ | |||||||||
| Taurine | √ | √ | √ | [ | ||||||
| Serine | √ | √ | [ | |||||||
| Choline | √ | √ | √ | √ | [ | |||||
|
| √ | [ |
Other metabolites in cerebral ischemia.
| Metabolites | Plasma | Serum | CSF | Cortex | Hippocampus | Striatum | White matter | Thalamus | Midbrain | Whole brain tissue | Pineal body, olfactory bulb | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Choline phosphate | √ | [ | ||||||||||
| Malate | √ | √ | √ | [ | ||||||||
| Citrate | √ | √ | √ | [ | ||||||||
| Succinate | √ | √ | [ | |||||||||
| Creatinine | √ | [ | ||||||||||
| 2-Hydroxybutyric acid | √ | [ | ||||||||||
| Creatine | √ | √ | √ | √ | [ | |||||||
| Glutamate | √ | √ | √ | √ | √ | [ | ||||||
|
| √ | √ | √ | [ | ||||||||
| Malonate | √ | [ | ||||||||||
| Alpha-D-glucose | √ | [ | ||||||||||
| Carnosine | √ | [ | ||||||||||
| Nicotinamide adenine dinucleotide (NAD+) | √ | √ | [ | |||||||||
| NG-nitro-L-arginine methyl nester (L-NAME) | √ | [ | ||||||||||
| N-Acetylaspartate (NAA) | √ | √ | √ | √ | √ | √ | √ | [ | ||||
| N-Acetylaspartylglutamate (NAAG) | √ | √ | √ | [ | ||||||||
| 6-Deoxy-6-[18F]fluoro-L-ascorbic acid | √ | [ | ||||||||||
| 3-Methoxy-4-hydroxyphenylglycol (HMPG) | √ | √ | √ | √ | √ | [ | ||||||
| 3-Hydroxypropyl mercapturic acid | √ | √ | √ | √ | √ | [ | ||||||
| Glycerophosphoric acid | √ | √ | [ | |||||||||
| Glutathione (GSH) | √ | √ | [ | |||||||||
| Disulfide (GSSG) | √ | √ | [ | |||||||||
| Myo-inositol | √ | √ | √ | √ | [ | |||||||
| Betaine | √ | [ | ||||||||||
| Pyruvate | √ | √ | [ | |||||||||
| Lactate | √ | √ | √ | √ | √ | √ | √ | √ | [ | |||
| 3,4-Dihydroxyphenylacetate (DOPAC) | √ | √ | √ | √ | √ | [ | ||||||
| Homovanillic acid (HVA) | √ | √ | √ | √ | √ | [ | ||||||
| Nicotinuric acid | √ | [ | ||||||||||
| Fumarate | √ | [ | ||||||||||
| Glucose 6-phosphate | √ | √ | [ | |||||||||
| Formate | √ | [ | ||||||||||
| Acetate | √ | √ | [ | |||||||||
| Ascorbate | √ | √ | √ | [ | ||||||||
| Taurine | √ | √ | √ | [ | ||||||||
| Alpha-2-Ketoisovaleric acid | √ | [ | ||||||||||
| 3-Hydroxybutanoic acid | √ | [ | ||||||||||
| 3-Hydroxyisovalerate | √ | [ | ||||||||||
| Acetone | √ | [ | ||||||||||
| Acetic acid | √ | [ | ||||||||||
| Oxaloacetate | √ | [ | ||||||||||
| Dimethylamine | √ | [ | ||||||||||
| Glycerol | √ | [ | ||||||||||
| D-Fructose | √ | [ | ||||||||||
| Aminoguanidine | √ | [ | ||||||||||
| Polyamines | √ | √ | √ | [ | ||||||||
| Putrescine | √ | √ | √ | [ | ||||||||
| Spermidine | √ | √ | √ | [ | ||||||||
| Spermine | √ | √ | √ | [ |
Top 10 relational pathway list (p < 0.01).
| Label |
| Adjusted | In background | In set | In set/in background% |
|---|---|---|---|---|---|
| Metabolic pathways | 5.51 | 4.24 | 1455 | 61 | 4.2 |
| Citrate cycle (TCA cycle) | 4.39 | 1.69 | 20 | 8 | 40.0 |
| Pyrimidine metabolism | 4.45 | 1.14 | 59 | 10 | 16.9 |
| Tyrosine metabolism | 4.99 | 8.56 | 76 | 10 | 13.2 |
| Parkinson's disease | 5.56 | 8.56 | 13 | 5 | 38.5 |
| Glycine, serine, and threonine metabolism | 9.36 | 1.12 | 49 | 8 | 16.3 |
| Alanine, aspartate, and glutamate metabolism | 1.01 | 1.12 | 24 | 6 | 25.0 |
| Oxidative phosphorylation | 1.79 | 1.64 | 16 | 5 | 31.3 |
| Neuroactive ligand-receptor interaction | 1.91 | 1.64 | 128 | 15 | 11.7 |
| Butanoate metabolism | 2.21 | 1.70 | 40 | 7 | 17.5 |
Figure 1Metabolic network of changed metabolites in cerebral ischemia. Bold type: metabolites already tested in rat. Gray type: metabolites not yet tested in rat.